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Available online 25 July 2016Melanoma is a cancer that arises frommelanocytes, specialized pigmented cells that are found predominantly in
the skin. The incidence of malignant melanoma has significantly increased over the last decade. With the devel-
opment of therapy, the survival rate of some kind of cancer has been improved greatly. But the treatment ofmel-
anoma remains unsatisfactory. Much of melanoma's resistance to traditional chemotherapy is believed to arise
intrinsically, by virtue of potent growth and cell survival-promoting genetic alteration. Therefore, significant at-
tention has recently been focused on differentiation therapy, as well as differentiation inducer compounds. In
previous study, we found isoliquiritigenin (ISL), a natural product extracted from licorice, could induce B16F0
melanoma cell differentiation. Here we investigated the transcriptional response of melanoma differentiation
process induced by ISL and all-trans-retinoic acid (RA). Results showed that 390 genes involves in 201 biochem-
ical pathwayswere differentially expressed in ISL treatment and 304 genes in 193 pathways in RA treatment. Dif-
ferential expressed genes (DGEs, fold-change (FC) ≥ 10)with the function of anti-proliferative and differentiation
inducing indicated a loss of grade malignancy characteristic. Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis indicated glutathionemetabolism, glycolysis/gluconeogenesis and pentose phosphate pathway
were the top three relative pathway perturbed by ISL, and mitogen-activated protein kinase (MAPK) signaling
pathway was the most important pathway in RA treatment. In the analysis of hierarchical clustering of DEGs,
we discovered 72 DEGs involved in the process of drug action. We thought Cited1, Tgm2, Xaf1, Cd59a, Fbxo2,
Adh7may have critical role in the differentiation of melanoma. The evidence displayed herein confirms the crit-
ical role of reactive oxygen species (ROS) in melanoma pathobiology and provides evidence for future targets in
the development of next-generation biomarkers and therapeutics.
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t@sohu.com,resistance ofmelanoma cells. Nevertheless, themechanisms underlying
such a radio/chemo-resistant cell phenotype remain mostly unknown
(Bajetta et al., 2002). Thus, looking for effective ways to control the oc-
currence, development of melanoma is pressing (Facchetti et al., 2007).
Tumor differentiation is a modality aimed at re-activating endogenous
differentiation programs in cancer cells and induces cancer cells to
stop proliferating and to express characteristics of normal cells. Differ-
entiation therapy is different from radio/chemotherapy by its less
toxic and drug resistance. Early successes in “differentiation therapy”
were achieved in the treatment of promyelocytic leukemiawith retinoic
acid (Sell, 2005). But less development of differentiation-based therapy
are found in solid tumours. In the case of melanoma, a number of cell
lines thought to represent ‘blocked’ stages of melanoma differentiation
have been isolated and studied (Herlyn et al., 1985; Herlyn et al., 1980;
87X. Chen et al. / Gene 592 (2016) 86–98Watkins et al., 1982). Discovery of new cancer-specific differentiation
inducers and elucidation of the mechanism underlying cancer cell dif-
ferentiation holds promise for developing improved therapies for mela-
noma (Barres & Dugas, 2008; Krissansen et al., 2003).
The mouse melanoma cell line B16 was isolated from C57 BL/6 mice
(Potop et al., 1984). Some studies demonstrated that B16 cells can be
induced to differentiate into mature melanocyte-like cells by treatment
with dimethyl sulfoxide(DMSO), dimethyl thiourea, sodium butyrate,
histidinol (Nordenberg et al., 1985; Nordenberg et al., 1986;
Nordenberg et al., 1987; Nordenberg et al., 1989; Nordenberg et al.,
1990), cAMP-elevating agents such as a melanocyte-stimulating hor-
mone (a-MSH) (Engan et al., 1995), signal transduction pathway inhib-
itors (Buscà et al., 1996), mannosylerythritol lipid (Zhao et al., 2001),
Alteronol (Wang et al., 2015) and all-trans-retinoic acid (RA) which is
widely used as a differentiation inducer (Estler et al., 2008). However,
compounds tested so far did not seem to be suitable for immediate clin-
ical evaluation except RA. Natural products and their derivatives which
possess the advantages of hypotoxicity and extensivematerial have his-
torically been invaluable as a source of therapeutic agents (Liu, 2004;
Walle &Halushka, 2001; Park et al., 2008). The past few years, however,
have seen a renewed interest in the use of natural compounds and,
more importantly, their role as a differentiation inducer (Amin &
Buratovich, 2007; Liu et al., 2010a; Robles-Fernández et al., 2013).
Some natural products like Theophylline (Kreider et al., 1975a), lupane
triterpenes (Hata et al., 2006), 5,7-dimethoxycoumarin (Alesiani
et al., 2008) have showed the activity of inducing tumor differentia-
tion. The modern tools of chemistry and biology-in particular, the
various ‘-omics’ technologies, now allow scientists to detail the
exact nature of the biological effects of natural compounds on the
human body, as well as to uncover possible synergies, which holds
much promise for the development of differentiation therapy against
many devastating diseases, including melanoma.
The resistance ofmelanoma to existing treatmentmodalities and the
rapid rise in its incidence (Lens & Dawes, 2004; Beddingfield, 2003) un-
derscore the importance of acquiring a better understanding of the
pathogenesis of this disease. Melanoma progression and metastasis is
traditionally modeled as a stepwise process with the initial mutagenic
event occurring in amelanocyte in the epidermis, with furthermutation
resulting in the proliferation passing through nevus and dysplastic
nevus phases. It is reported by research that reveals melanocytes can
be transformedwith oncogenes and acquiremalignant/invasive charac-
teristics (Chudnovsky et al., 2005). Furthermore, the tyrosinase promot-
er, expressed in melanocytes, has been shown to induce melanoma
when driving oncogenic proteins SV40E (Kelsall & Mintz, 1998) and
N-Ras (Atkinson et al., 2015). Evidence supports the presence of mela-
noma stem-like cells (Fang et al., 2005; Roesch, 2015). First, melanomas
show phenotypic heterogeneity both in vivo and in vitro, suggesting an
origin from a cell with multilineage differentiation abilities (Grichnik
et al., 2006). Second, melanoma cells often express developmental
genes (Liu et al., 2014). Third, melanoma cells can differentiate into a
wide range of cell lineages, including neural, mesenchymal, and endo-
thelial cells (Reed et al., 1999; Fang et al., 2001). Studies on metastatic
melanoma lines have revealed that melanomas are believed to arise
from a mature, differentiated melanocyte. Evidence also indicated an
existence of re-differentiation for melanoma self-renewal that drives
tumorigenesis. An early study revealed that theophylline involved in
the regulation of B16 melanoma cells proliferation and differentiation,
the theophylline-treated cells contained ten times the melanin and an
elevated cAMP content compared to the controls (Kreider et al.,
1975b); subsequent studies showed that DMSO also showed anti-
proliferative and differentiating effects; vitamin A (retinoids) regulated
mouse melanoma growth and differentiation, induces a six-fold to
eight-fold increase in protein kinase C (PKC) α RNA and protein,
which is not a direct target of retinoic acid (RA). It has been proposed
that melanoma cells intrinsically possess a genetic programme predis-
posing them to exacerbated metastatic features (Gupta et al., 2005).The most remarkable gene is the microphthalmia-associated transcrip-
tion factor (MITF), which is the keymolecular switch betweenmouse or
human melanoma initiating cells and their differentiated progeny. In-
deed, MITF was identified as the master gene in melanocyte differenti-
ation, which it does by controlling the expression of melanogenic
enzymes (TYR, TYRP1, DCT). Later, MITF was shown to regulate the ex-
pression of genes involved in all steps of melanocyte differentiation, in-
cluding dendricity (DIA), melanosome biogenesis (SILVER, OA1) and
melanosome transport (RAB27a) (Cheli et al., 2011). Concomitantly,
King et al. (2001) reported that MITF expression was maintained in
N85% of melanoma, and a MITF gene amplification has been found in
N20% of metastatic melanomas. As is the case for many other neo-
plasms, physiological differentiation of melanocytes and metastatic
melanoma development share common signaling pathways, such as
ERK and PI3 kinase pathways (King et al., 2001).Many of these changes,
originally discovered through examination of tumor biopsies, have been
functionally validated using experimental models. But in this way re-
searchers may cost too much but gain little. Estler et al. (2008) invited
microarray to determine gene expression changes during retinoic
acid-induced growth arrest and differentiation of melanoma to gain a
globe knowledge of RA “normalized” the expression of genes involved
in energy metabolism, DNA replication, DNA repair and differentiation.
With the help of microarray, researchers may get an easier process to
study the mechanism of pharmacological effects of drugs. Over the
past 10 years, introduction of high-throughput next-generation se-
quencing (NGS) technologies have revolutionized transcriptomics by
providing opportunities for multidimensional studies of cellular
transcriptomes. Thus, it becomes possible because large-scale expres-
sion data are acquired at a single-base resolution. As amain quantitative
transcriptome profiling platform, RNA-seq has been considered a new
experimental method to replace microarray.
In our previous study, we have found isoliquiritigenin (ISL) derived
from traditional Chinese medicine licorice could induce the differentia-
tion in mouse melanoma B16F0 cells (Liu et al., 2010b; Wang et al.,
2010a;Wang et al., 2010b). But we only profiled the role of reactive ox-
ygen species (ROS) during ISL induced B16F0 cell differentiation. To
gain additional insight into themolecular alterations and cellular events
of melanoma differentiation, we performed the transcriptome profiling
analysis of ISL/RA induced B16F0 cell differentiation using RNA-Seq.
2. Materials and methods
2.1. Cell line and cell culture
B16F0 cells were purchased from China Center for Type Culture Col-
lection (CCTCC,Wuhan, China). The cellsweremaintained in RPMI 1640
medium supplemented with 10% fetal bovine serum, and 100 U/mL
penicillin, 100 μ g/mL streptomycin at 37 °C with 5% CO2. The cells
were split every 2 day and were diluted 1 day before each experiment.
2.2. Preparation of a cDNA library for RNA-Seq
Total RNA was extracted from untreated (C) or isoliquiritigenin/all-
trans-retinoic acid (ISL/RA) treated B16F0 cells using TRIzol® reagent
(Invitrogen, Burlington, ON, Canada) and then treatedwith DNase to re-
move potential genomic DNA contamination according to the
manufacturer's protocol. The yield and purity of RNA were assessed by
determination of the absorbance (Abs) at 260 and 280 nm. RNA was
only used when the Abs260 nm/Abs280 nm ratio was N1.8. RNA integ-
rity was checked using a 1% agarose gel with the RNA 6000 Nano Assay
Kit and Agilent 2100 Bioanalyzer. The extracted total RNAwas stored at
−70 °C for later use.
The total RNA was extracted and mRNA of B16F0 cells was enriched
by using the oligo(dT) magnetic beads. Adding the fragmentation buff-
er, the mRNA was interrupted to short fragments (about 200 bp), then
the first strand cDNA was synthesized by random hexamer-primer
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and DNA polymerase I to synthesize the second strand. The double-
stranded cDNA was purified with QiaQuick PCR extraction kit and
washed with EB buffer for end repair and single nucleotide A (adenine)
addition. Finally, sequencing adaptors were ligated to the fragments.
The required fragments was purified by agrose gel electrophoresis and
enriched by PCR amplification. The library products was sequenced
and 50 bp sequences were generated via the Illumina sequencing plat-
form (HiSeqTM 2000).
2.3. Mapping reads to the reference genome and differential expression
(DE) detection, differential gene expression analysis and clustering
Prior tomapping reads to the reference database (NCBI37/mm9),we
filtered all reads to remove adaptor reads and low-quality reads (the
percentage of quality value ≤5 bases was N50% in a read) before data
analysis. The remaining reads were mapped to the reference gene set
using SOAPaligner/soap2 (Li et al., 2009), allowing up to two base
mismatches.
To obtain normalized gene expression levels, we calculated reads by
the reads per kb per million reads (RPKM) method (Mortazavi et al.,
2008). The cutoff value for determining gene transcriptional activity
was determined based on a 95% confidence interval for all RPKM values
for each gene. A previous described rigorous significance test (Audic &
Claverie, 1997), with some modifications by BGI-Shenzhen company
was utilized to identify significant differentially expressed genes be-
tween two samples. Also, the false discovery rate was calculated based
on the methods published by Benjamini Y and Yekutieli D (Benjamini
& Yekutieli, 2001). We used false discovery rate (FDR) ≤ 0.001 and the
absolute value of log2Ratio ≥ 1 as the threshold to judge the significance
of gene expression difference (Storey and Tibshirani, 2003).
For an optimal comparison of the results, hierarchical clusteringwas
performed to identify candidate genes involved in specific gene expres-
sion patterns using with cluster 3.0 software (de Hoon et al., 2004) and
Java Treeview (Saldanha, 2004). The parameter of cluster 3,0 used in
this research are “-g 7 -e 7 –ma”. The similarities between gene expres-
sion data was measured by Euclidean distance. 2D clustering diagram
was used to compare gene expression levels for C-vs-ISL and C-vs-RA.
2.4. Quantitative PCR (qPCR) analysis
In order to verify the DGE results, we used qPCR analysis. The RNA
samples used for the qPCR assayswere both the same as for the DGE ex-
periments and independent RNA extractions from biological replicates.
qPCRs were done on the Lightcycler480 (Roche), with SYBR-Green de-
tection (SYBR PrimeScript RT-PCR Kit, TaKaRa Biotechnology Co., Ltd.),
according to the manufacture's instruction. Each cDNA was analyzed
in triplicate, after which the average threshold cycle (Ct) was calculated
per sample. The relative expression levels were calculated with the 2−Δ
ΔCt method. The results were normalized to the expression level of
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and relative to
the C sample (control group: B16F0 cells treated without drugs).
2.5. Gene Ontology (GO) analysis
Gene Ontology (GO) is an international standardized gene function-
al classification system which offers a dynamic-updated controlled vo-
cabulary and a strictly defined concept to comprehensively describe
properties of genes and their products in any organism. GO has three
ontologies: molecular function, cellular component and biological pro-
cess. The basic unit of GO is GO-term. Every GO-term belongs to a type
of ontology.
GO enrichment analysis provides all GO terms that significantly
enriched in DEGs comparing to the genome background, and filter the
DEGs that correspond to biological functions. The DAVID web tool
(http://david.abcc.ncifcrf.gov/) was used to identify significantlyenriched GO terms among the given list of genes that are differentially
expressed (Huang da et al., 2009). The p-value analyzed by DAVID
goes through Bonferroni Correction, taking corrected p-value ≤0.05 as
a threshold. GO terms fulfilling this condition are defined as significantly
enriched GO terms in DEGs. This analysis is able to recognize the main
biological functions that DEGs exercise. GO categories with p-value
b0.01 were considered significant.
2.6. Pathway analysis of differential expression genes(DEGs)
Pathway analysis is mainly based on the Kyoto Encyclopedia of
Genes and Genomes (KEGG) database. Two-side Fisher's exact test
with a multiple testing was used to analysis pathway enrichment,
which identified significantly enriched metabolic pathways or signal
transduction pathways in DEGs comparing with the whole genome
background. The calculating formula is the same as that in GO analysis.
Here N is the number of all genes that with KEGG annotation, n is the
number of DEGs in N, M is the number of all genes annotated to specific
pathways, and m is number of DEGs in M. We chose only pathway cat-
egories that had a Q-value ≤ 0.05.
3. Results
3.1. Illumina sequencing and aligning to the reference genome
An immediate application of our RNA sequence data included gene
expression profiling at cells treated with or without drug. RNA-seq
was employed to analyze variations in gene expression of the B16F0
melanoma cell transcriptome. We sequenced three cDNA libraries (C,
ISL and RA) using Illumina (single-end) sequencing technology, and ob-
tained a total of 19.38million raw readswith an average length of 50 bp,
a total of approximately 968.98 million base pairs (Mbp). After removal
of adaptor sequences, ambiguous reads and low-quality reads in which
the percentage of unknown bases (N) is N10% and the percentage of the
low-quality base (base with quality value ≤5) is N50%, a total of
5,925,877 (C) and 6,136,095 (ISL) and 5,896,974 (RA) high-quality
clean reads comprised of 290,367,973 nucleotides (290 M) and
300,668,655 nucleotides (300 M) and 288,951,726 nucleotides
(288 M) were generated from the C, ISL and RA libraries, respectively.
These short reads were aligned to the mouse reference gene sequences
and mouse reference genome sequences (mm9) using SOAPaligner/
SOAP2 (Li et al., 2009). Of the total reads in 3 samples, 85.83% matched
either to a unique (67.35%) or to multiple (18.48%) genomic locations;
the remaining 14.17% were unmatched (Table 1), because only reads
aligning entirely inside exonic regions will be matched (reads from
exon-exon junction regions will not match).
3.2. Global analysis of gene expression
One of the primary goals of RNA-seq is to compare gene expres-
sion levels between samples. Based on the numbers of reads mapped
to every gene in the reference database, we measured gene expres-
sion in reads per kilobase per million mapped sequence reads
(RPKM), a normalized measure of read density described in RPKM
method (Mortazavi et al., 2008).
A total of 12,877 (C), 13,121 (ISL) and 12,945 (RA) genes were de-
tected in the samples. The removal of partial overlapping sequences
yielded 12,031 genes, providing abundant data for the analysis of ISL
or RA induced melanoma differentiation process. Their expression in
the three cDNA libraries is summarized in Fig. 1 Venn diagram shows
the distribution of expressed genes from C (control B16F0 melanoma
cell), ISL (ISL treated B16F0 melanoma cell), and RA (RA treated B16F0
melanoma cell). Among these genes, 286 were co-expressed in C and
ISL, 219 were co-expressed in C and RA, and 316 were co-expressed in
ISL and RA. The number of specifically expressed genes was 488 (C),
379 (ISL), and 341 (RA), respectively.
Table 1
Summary of read numbers based on the RNA-Seq data from C, ISL and RA.
Map to genome sequence
C ISL RA

























89X. Chen et al. / Gene 592 (2016) 86–983.3. Differential expression genes (DEGs) after ISL or RA treatment
To identify genes showing significant change in expression during
different drug treatment, the differentially expressed genes after ISL or
RA treatment were detected based on the criteria of significance
(FDR ≤ 0.001 and log2ratio ≥ 1) (Marioni JC et al., 2008). As a result, a
total of 487 significantly changed genes were detected between the C
and ISL, of which 332 and 155 were found to be up-regulated and
down-regulated, respectively (Fig. 2 and Table S1). Meanwhile, be-
tween the C and RA, there were 368 DEGs that were significantly differ-
entially expressed, with 234 up-regulated and 134 down-regulated
(Fig. 2 and Table S2). This suggests that the number of differently
expressed genes between C and ISL is larger than that between C and
RA. Between the R and ISL libraries, a total of 579 DEGs were detected,
with 321 up-regulated genes and 258 down-regulated genes (Fig. 2
and Table S3). And the 10 most up- and down-regulated genes treated
after ISL or RA are listed in Tables 2 and 3.3.4. Validation of DGEs data by qPCR
To validate DE genes identified by Solexa sequencing, we randomly
selected 6 genes for qPCR confirmation. The set included two down-
regulated genes(Creb5, Cd74)and four up-regulated genes (Gsta3,
Fcna, Efhd1, Spint1). Data were presented as fold changes in geneFig. 1. Venn diagram showing the genes expressed in each of the three samples (ISL, RA
and C). Among these genes, 12,031 are expressed at all three samples, 286 are co-
expressed in ISL and C, 219 are co-expressed in RA and C, and 316 are co-expressed in
ISL and RA. The number of sample-specifically expressed genes is 488 (ISL), 379 (RA),
and 341(C), respectively.expression normalized to the GAPDH gene and relative to the C sample.
Virtually all the genes show concordant direction of fold change be-
tween RNA-seq and qPCR. (Fig. 3). qPCR analysis (both pooling samples
and independent RNA extractions from biological replicates) confirmed
the direction of change detected by RNA-seq analysis. This correlation
indicated the reliability of RNA-seq results. The primers used in qPCR
analysis were showed in Table S4.
3.5. Clustering of DEGs in different drug treatment
Geneswith similar expression patterns usually have same functional
correlation, so we went further cluster analysis based on the k-means
method using Pearson's correlation distance, so that we could deter-
mine the similarity in relative change for each transcript across the set
of different drug treatment, and how those changes were similar or dif-
fered between transcripts. These data were then subjected to hierarchi-
cal clustering using the Pearson correlation as the distancemetric (Fig. 4
& Table S5).
Two-dimensional hierarchical clustering classified 72 differential
expression (intersection between C-VS-ISL and C-VS-R) profiles into
two expression cluster groups (Clusters 1 and Clusters 2) according to
the similarity of their expression profiles, representing the number of
profiles indicated using figure of merit analysis. Clusters 1 contained
genes negatively modulated throughout the ISL or RA treatment,
while genes expressed in Clusters 2 showed positively or negatively
modulated in the ISL or RA treatment. Clusters 1, with 30 genes whose
expression showed a similarity of their expression profiles, and among
these 10 genes differently modulated during the treatment of ISL or
RA. Cluster 2 was composed of 42 genes that positively modulated.
The cluster analysis showed that ISL and RA has different regulatory
pattern.
3.6. Functional analysis of DEGs during ISL or RA treatment based on RNA-
seq data
To better characterize the effects of ISL andRA in biological processes
we conducted GO enrichment analysis using DAVID (Bonferroni-
corrected, FDR ≤ 0.05), with differentially expressed genes. Based on se-
quence homology, 434 and 340 DEGs could be categorized into 232 and
278 functional groups during ISL treatment andRA treatment (Fig. 5 and
Table S6). In the threemain categories (biological process, cellular com-
ponent andmolecular function) of the GO classification, therewere 150,
29 and 53 functional groupswith ISL treatment and210, 34 and 34 func-
tional groups with RA treatment, respectively (Fig. 5). Among these
groups, the GO terms glucose metabolic process (GO: 0006006) in the
biological process categories and response to stimulus in the biological
process positive regulation of apoptosis (GO: 0043065) were both
dominant in the treatment both of ISL and RA. We also noticed a high
percentage of genes from oxidation reduction (GO: 0055114), cell
death (GO: 0008219), death (GO: 0016265), apoptosis (GO: 0006915)
and three glycometabolism process (glucose metabolic process,
GO:0006006; hexose metabolic process, GO:0019318; monosaccharide
metabolic process, GO:0005996) with the treatment of ISL. And a high
percentage of genes from regulation of transcription from RNA poly-
merase II promoter (GO: 0006357), regulation of apoptosis (GO:
0042981), regulation of programmed cell death (GO: 0043067), regula-
tion of cell death (GO: 0010941) andnegative regulation of biosynthetic
process (GO: 0009890) with the treatment of RA. These data suggest
that the cell structure or function and signal transducing processes are
the major processes during the treatment of ISL or RA, and that their
overrepresentationmay be due to the differentiation ofmelanoma cells.
3.7. Pathway analysis of DEGs during the treatment of ISL or RA
To identify the biological pathways that are active in ISL or RA treat-
ed B16F0 cells, we mapped the detected genes to reference canonical
Fig. 2. Expression level and statistics of the differentially expressed genes (DEGs) between samples. (A) Expression level of DEGs in C-vs-ISL. (B) Expression level of DEGs in C-vs-RA.
(C) Expression level of DEG in RA-vs-ISL. (D) Changes in gene expression profile among C, ISL, RA. The number of up-regulated and down-regulated genes in C-VS-ISL, C-VS-RA and
RA-VS-ISL are summarized. Between the C and ISL libraries, there are 332 genes up-regulated and 155 genes down-regulated, while there are 234 up-regulated genes and 134 down-
regulated genes between the C and RA libraries.
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(http://www.genome.ad.jp/kegg/) (Park et al., 2008) (Fig. 6). Of the
total 16,857 genes with pathway annotation, 390 and 304 were
assigned to 201 and 193 KEGG pathways with the treatment of ISL
and RA respectively. Those pathways with the greatest representationTable 2
Top 10 upregulated and downregulated genes after ISL treatment.
Symbol Description
Up-regulated
Gsta3 Glutathione S-transferase, alpha 3
Spta1 Spectrin alpha, erythrocytic 1
Gdf15 Growth differentiation factor 15
Lipt2 Lipoyl(octanoyl) transferase 2 (putative)
Slc7a11 Solute carrier family 7 (cationic amino acid transporter, y + system
Blvrb Biliverdin reductase B (flavin reductase (NADPH))
A530050N04Rik RIKEN cDNA A530050N04 gene
Srxn1 Sulfiredoxin 1 homolog (S. cerevisiae)
Xaf1 XIAP associated factor 1
Fbxo2 F-box protein 2
Down-regulated
Creb5 cAMP responsive element binding protein 5
Dsp Desmoplakin
Stc1 Stanniocalcin 1
Synm Synemin, intermediate filament protein
Col12a1 Collagen, type XII, alpha 1
Tet1 Tet methylcytosine dioxygenase 1
Gm13889 Predicted gene 13889
Apln Apelin
Fyb FYN binding protein
Cacna1a Calcium channel, voltage-dependent, P/Q type, alpha 1A subunitby unique genes were for glutathione metabolism (13/390 DEGs);
glycolysis/gluconeogenesis (13/390 DEGs); and pentose phosphate
pathway (7/390 DEGs) during the treatment of ISL. And the majority
of the differentially expressed genes were found to be associated with
MAPK signaling pathway (23/304 DEGs), carbohydrate digestion andGene ID Fold change p-Value FDR
14859 533.35 7.56E−12 1.36E−10
20739 13.96 4.17E−07 3.88E−06
23886 11.31 2.62E−19 8.41E−18
67164 9.63 9.46E−05 5.26E−04
), member 11 26570 9.17 1.75E−143 5.20E−141
233016 8.11 2.97E−184 1.23E−181
442846 7.54 7.19E−09 8.82E−08
76650 7.12 0 0
327959 6.74 1.41E−06 1.19E−05
230904 6.41 7.13E−27 3.45E−25
231991 −117.72 1.10E−05 7.77E−05
109620 −16.62 1.06E−04 5.84E−04
20855 −15.16 1.59E−33 1.01E−31
233335 −14.19 4.09E−10 6.00E−09
12816 −9.00 5.30E−06 4.01E−05
52463 −7.83 1.46E−32 9.10E−31
620695 −7.27 1.08E−04 5.92E−04
30878 −7.06 7.73E−07 6.85E−06
23880 −6.53 3.34E−08 3.70E−07
12286 −6.35 8.26E−10 1.16E−08
Table 3
Top 10 upregulated and downregulated genes after RA treatment.
Symbol Description Gene ID Fold change p-Value FDR
Up-regulated
Fcna Ficolin A 14133 1492.44 1.49E−28 8.17E−27
Efhd1 EF hand domain containing 1 98363 885.51 2.34E−23 1.07E−21
Plekhb1 Pleckstrin homology domain containing, family B (evectins) member 1 27276 50.07 2.71E−14 7.63E−13
Vdr Vitamin D receptor 22337 42.04 2.76E−77 4.26E−75
Akap12 A kinase (PRKA) anchor protein (gravin) 12 83397 39.87 0 0
Lcn2 Lipocalin 2 16819 22.48 2.34E−06 2.69E−05
Dhrs3 Dehydrogenase/reductase (SDR family) member 3 20148 22.00 0 0
Ppm1j Protein phosphatase 1J 71887 20.44 8.82E−06 9.02E−05
Lif Leukemia inhibitory factor 16878 20.11 1.19E−88 2.18E−86
Tmem141 Transmembrane protein 141 51875 16.54 4.74E−41 3.56E−39
Down-regulated
Ptgir Prostaglandin I receptor (IP) 19222 −15.01 5.96E−11 1.28E−09
Cyp4b1 Cytochrome P450, family 4, subfamily b, polypeptide 1 13120 −11.94 2.62E−13 6.90E−12
Sgcg Sarcoglycan, gamma (dystrophin-associated glycoprotein) 24053 −6.25 1.49E−13 3.98E−12
Mgll Monoglyceride lipase 23945 −5.81 4.80E−75 7.01E−73
Gsta2 Glutathione S-transferase, alpha 2 (Yc2) 14858 −5.68 2.93E−05 2.68E−04
Ano3 Anoctamin 3 228432 −5.67 1.35E−74 1.95E−72
Cav1 Caveolin 1, caveolae protein 12389 −5.61 1.48E−33 9.28E−32
Dusp2 Dual specificity phosphatase 2 13537 −5.22 1.05E−09 2.03E−08
Ahnak AHNAK nucleoprotein (desmoyokin) 66395 −5.08 0 0
Synm Synemin, intermediate filament protein 233335 −5.02 1.68E−06 1.99E−05
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ment of RA.
4. Discussion
In this study, we have applied high-throughput single-end sequenc-
ing of cDNA (RNA-seq) as a systematic means to investigate the gene
expression profiles in ISL/RA treated with or without melanoma cells.
We identified 487 and 368 DEGs for the ISL and RA treatment including
previously uninvestigated molecules. A pathway analysis of these DEGs
revealed that the most significant biofunction in ISL treatment was the
“glutathionemetabolism”, and “MAPK signaling pathway” by in RA treat-
ment. We also found that the glycolysis/gluconeogenesis pathway and
Pentose phosphate pathway and other sets of metabolic pathway-
related genes were significantly down-regulated by ISL. These results
point to the critical role that anti-oxidative defense and glycometabolism
in the B16mousemelanoma cell differentiation inducedby ISL, andMAPK
signaling in the RA treatment. This finding facilitates the understanding
of melanoma differentiation process and leads a way for new drug
discovery.
To our knowledge, this is thefirst reported study of extensive chang-
es in gene expression of ISL-treated melanoma cells. Although another
study have examined the gene expression treated by RA usingmicroar-
ray (Estler et al., 2008), the molecular mechanisms remain unclear. In
contrast to RNA-seq, expression microarrays have a number of limita-
tions (e.g., reliance on existing knowledge about the genome sequence,
background noise and lower dynamic range). We therefore performed
RNA-seq to generate a global view of drug induced differentiation of
melanoma. Comparison of the identity of RA-regulated genes by RNA-
seq in this study reported here reveals some commonality of genes
such as akap12, ATPase, Ltbp1, Prkca, Anpep and zinc finger protein,
but also a number of different gene expression changes. Possible expla-
nations for these differences are analysis of different technology to de-
tect, and different method of statistical analysis.
By focusing on only those genes which significantly N10 fold in-
creased or decreased in samples a list of common ‘top hits’was created
(Tables 2 and 3).We discovered novel 7 genes (3 up-regulated, 4 down-
regulated) altered after the ISL treatment, and 22 genes (20 up-
regulated, 2 down-regulated) in the RA treatment. There was a major
increase in the number of genes which expression changed at 48 h of
compounds treatment that were up-regulated outnumbered those
that were down-regulated. When genes were ranked by fold-change(FC), Gsta3 (amember of a groupof zinc-finger transcription factors) in-
volved in cell development and differentiation was one of the most up-
regulated genes overall with a 533.35-fold increase treated after ISL
treatment. Li Y et al. found Gsta3 played an important role in the pre-
vention of bladder cancer progression and metastasis by inhibiting cell
migration and invasion (Li et al., 2014).Moreover, it has been suggested
decreased expression of Gsta3 accompanied with increasing tumor
grade in breast cancer (Thewes et al., 2010). The increasing expression
of Gsta3 in our data demonstratedmelanoma cells revealed a gradema-
lignancy reduction characteristic. Jowsey IR et al. have identified Gsta3
as a novel adipocyte differentiation-associated protein (Jowsey et al.,
2003a). Previous studies also showed transcription factor Gsta3was es-
sential for differentiation of both Th2 cells and Ilc2 (KleinJan et al., 2014)
and had potential value in differentiating small cell carcinomas of pros-
tate origin from those of bladder origin (Bezerra et al., 2014). Gsta3 also
played a role in the regulation of proliferation and/or differentiation
processes in humanprimary keratinocytes (Masse et al., 2014). Further-
more, it has been reported Gsta3 as a direct target for Notch signaling is
a critical element determining inductive Th2differentiation and limiting
Th1 differentiation (Amsen et al., 2007). Growth differentiation factor
15 (Gdf15), a member of the transforming growth factor-beta (TGF-
beta) super-family, was also up-regulated by ISL. Ichikawa T et al.
found TAp63-dependent induction of growth differentiation factor 15
(Gdf15) plays a critical role in the regulation of keratinocyte differenti-
ation (Ichikawa et al., 2008). Our finding indicated that Gsta3 andGdf15
may therefore be useful markers for evaluating ISL induced differentia-
tion of melanoma.
Significant expression change of genes are found in the RA-
treatment. Although, highly expressed gene Fcna and Plekhb1 which
fold-change is 1492.44 and 50.07 respectively, had no function been
ascribed to its predicted protein. Efhd1, which FC is 885.51, was
mentioned in the research of fraternal twins. Dutting S et al. found
Swiprosin-1/Efhd2. Swiprosin-2/Efhd1, two homologous EF-hand con-
taining calcium binding adaptor proteins, modulates apoptosis and dif-
ferentiation of neuronal and muscle precursor cells and swiprosin-2/
Efhd1 is part of a cellular response to oxidative stress (Dütting et al.,
2011). It has been reported that VDR expressed in cutaneous melano-
mas as marker of tumor progression (Kosiniak-Kamysz et al., 2014).
High VDR expression determines a less malignant phenotype and re-
lates to better prognosis for the progression of the disease. Akap12,
Rarb and Pmepa1 are genes with tumor suppressor properties (Flotho
et al., 2007; Yoon et al., 2007; Moison et al., 2014; Li & Li, 2015; Xu
92 X. Chen et al. / Gene 592 (2016) 86–98et al., 2003), which also were up-regulated by RA treatment. We also
found the increased expression of Dhrs3. Likewise there are numerous
reports that RA alters the expression of Rarb and Dhrs3 which have
functions in the bioactive of all trans retinoic acid. Retinoic acid receptor,
beta (Rarb) is one of the three subtypes of retinoic acid receptors (PAR),
which binds RA (Benbrook et al., 1988). The retinoic acid inducible
dehydrogenase reductase 3 (Dhrs3) is thought to function as a
retinaldehyde reductase that controls the levels of all trans
retinaldehyde, the immediate precursor for bioactive all trans retinoic
acid (Adams et al., 2014). Moreover, there are a variety of studies show-
ing Lif, Lgi4, Pmepa1 andGfra1 involve in the cell differentiation process
with a FC ≥ 10 enhanced. Sun L et al. found leukemia inhibitory factor
(LIF) playing divergent roles in different cell types: induces differentia-
tion in preadipocytes and, however, inhibits differentiation in pluripo-
tent murine embryonic stem (mES) cells (Sun et al., 2007). Lgi4 could
promote the proliferation and differentiation of glial lineage cells
throughout the developing peripheral nervous system (Nishino et al.,
2010). Pmepa1 was thought to be a transforming growth factor-beta-
induced marker of terminal colonocyte differentiation (Brunschwig
et al., 2003). He Z et al. discovered Gfra1 silencing in mouse spermato-
gonial stem cells results in their differentiation via the inactivation of
RET tyrosine kinase (He et al., 2007). However, no evidence and func-
tion research has been published that RA regulates Plekhb1, Ppm1j,
Tmem141 andGstm7whichwere up-regulated in our data. The increas-
ing expression of differentiation-related genes may give us a deep rec-
ognition of the mechanism of RA-induced melanoma differentiation
by RNA-seq and make up the shortage of microarray at the same time.
The possible functions of the assembled DGEs were analyzed
through their matching to the KEGG database, and the results indicated
that the largest number of DEGs were included in glutathione metabo-
lism, glycolysis/gluconeogenesis and pentose phosphate pathway (top
three pathway that DGEs significantly enrich) treated after ISL. This
finding indicates that anti-oxidative defense and glycometabolism is
critical process in the ISL-induced melanoma differentiation. This find-
ing is a complement to our previous research. In the current study, we
found that the anti-oxidative response-related genes Gsta3 and Gclm
were significantly up-regulated in glutathione metabolism treated
after ISL. Glutathione S-transferase A3 (Gsta3), belonging to the alpha
class glutathione S-transferases, are highly related and encode enzymes
with glutathione peroxidase activity. The peroxidase activity associated
with the GSTs is referred to as NonSe-GPX activity, which represents
one of the important antioxidantmechanisms that exist in cells for pro-
tection against hydroperoxides, classified as reactive oxygen species
(ROS) (Prohaska & Ganther, 1977). The significant increasing expres-
sion change by ISL indicated a cellular anti-oxidation adaptation pro-
cess. In addition, the dramatic expression profile of Gsta3 observed in
our RNA-seq data during ISL-induced melanoma differentiation also
raises important questions as to how the Gsta3 gene is regulated. Previ-
ous study showed that Nrf2 regulates Gsta3 gene expression in a num-
ber of mouse tissues (Jowsey et al., 2003b). Further studies are still
needed for the detailed explanation of the regulation of Nrf2 on Gsta3.
The rate-limiting enzyme in GSH synthesis is glutamate cysteine ligase
and polymorphisms in its catalytic and modifier subunits (Gclc and
Gclm) have been shown for compromised response to oxidative stress
amenable to in vitro and in vivo investigations (Schrottmaier, 2014;
Cole et al., 2011). Harris and colleagues assessed the effects of genetic
deletion of glutamate-cysteine ligase, modifier subunit (Gclm), which
mediates GSH synthesis, impaired tumor initiation and progression in
several mouse models of spontaneous tumor development and they
also found deficiency in Gclm led to a 75% decrease in GSH levels,
shifting the cells to a state of chronic oxidant stress (Harris et al.,Fig. 3. qPCR validation of RNA-seq data. Relative quantitation was carried out to measure chang
are expressed as the target/reference ratio of each sample normalized by the target/reference rat
change of transcript abundance in ISL (Fig. 4A) or RA (Fig. 4B) treated B16F0 cells compared to
sequencing; qPCR-B: the RNA samples from independent RNA extractions from biological repl2015). Consistent with this idea, Gclm-deficient cells exhibited in-
creased expression of the antioxidant transcription factor nuclear factor
(erythroid-derived 2)-like factor 2 (Nfe2l2, also known as Nrf2), which
may compensate for decreased GSH synthesis to facilitate cell survival.
This work suggested Gclm with an antioxidant ability could play a
major role in driving cancer progression and affect the phenotypic be-
havior of cancer cells, also prompt Nrf2 was one of upstream regulators
simultaneously. Nrf2 is a potent transcriptional activator and plays an
important role in cellular antioxidant defense. Nrf2 transcriptional tar-
gets include glutathione cysteine ligase (GCL), involved in the rate-
limiting step of biosynthesis of antioxidant glutathione; glutathione-
utilizing enzymes such as glutathione S-transferase (GST); and haeme
oxigenase 1 (HMOX1), involved in the catabolism of pro-oxidant
haeme (Jung & Kwak, 2013). The current paradigm of Nrf2 regulation
has mainly focused on oxidative stress-induced post-translational
mechanisms, including regulation by its negative regulators (Keap1,
Bach1, and b-TrCP), positive regulators (DJ1, p62, and p21), or protein
modifications (Chowdhry et al., 2013). Our profiling results of increas-
ing expression of Gata3 andGclm, target of Nrf2,may implicateNrf2 dis-
plays a potentially role in the melanoma differentiation mechanism
induced by ISL. We also found several known anti-oxidant enzymes
(Gstm6, Gsr, Gpx4, Gclc, Gstm1, G6pdx, Mgst1, Odc1) were elevated
in glutathione metabolism as a correlate to the ISL treatment
(Table S7). Based upon the gene expression profiles, we can conjecture
a shift of the cellular redox state towards a strongly changed cellular
milieu.
Glycolysis is regulated by slowing down or speeding up certain steps
in the glycolysis pathway. This is accomplished by inhibiting or activat-
ing the enzymes that are involved. The three regulated enzymes are
hexokinase (HK), phosphofructokinase (PFK-1), and pyruvate kinase
(PK). Our results showed the down-regulation of hexokinase 2 (HK2),
phosphofructokinase (PFK-1) and other enzymes like enolase 1B
(Eno1b), phosphofructokinase (Pfkp), triosephosphate isomerase 1
(Tpi1), lactate dehydrogenase A (Ldha), phosphoglucomutase 2
(Pgm2), glucose phosphate isomerase 1 (Gpi1), aldehyde dehydroge-
nase 16 family, member A1 (Aldh16a1) are directly associated with a
decrease in glycolysis treated after ISL. Furthermore, pseudogene 5069
(Gm5069) that have not been previously reported. Hexokinase 2
(HK2), coding for the first rate-limiting enzyme of glycolysis, has a crit-
ical role in cancer cells' proliferation among the top list of genes predict-
ed. In highly proliferative cancer cells, the up-regulation of glycolysis in
cancer cells (the “Warburg effect”) is common and has implications for
prognosis and treatment. And the highly glycolytic phenotype is sup-
ported by hexokinase (primarily HK 2) that is over expressed and
bound to the outer mitochondrial membrane via the porin-like protein
voltage-dependent anion channel (VDAC). This protein and the adenine
nucleotide transportermoveATP, newly synthesized by the innermem-
brane located ATP synthase, to active sites on HK 2. The abundant
amounts of HK 2 bind both the ATP and the incoming glucose producing
the product glucose-6-phosphate, also at an elevated rate. This critical
metabolite then serves both as a biosynthetic precursor to support cell
proliferation and as a precursor for lactic acid, the latter exiting cancer
cells causing an unfavorable environment for normal cells. Phospho-
fructokinase is an important control point in the glycolytic pathway,
since it is one of the irreversible steps and has key allosteric effectors,
AMP and fructose 2,6-bisphosphate (F2,6BP). The decreased expression
of Hexokinase 2 and phosphofructokinase suppress the “Warburg Ef-
fect” in cancer while helping prevent cell proliferation.
The pathophysiological status of solid malignant tumours is
characterised by pronounced tissue acidosis and hypoxia (Semenza,
2011) and by enhanced formation and accumulation of lactatees target gene expression in samples relative to an endogenous reference sample. Results
io of the calibrator. GAPDHwas used as a reference gene. The vertical axis indicates the fold
the control cells. (qPCR-P: the RNA samples from pooling samples that were used for deep
icates).
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Fig. 4. Hierarchical cluster analysis of gene expression based on log ratio RPKM data. The colour means Log2(Fold-change) of the differential expression profiles. Green represents lower
expression, red represents high expression, columns represent individual experiments, and rows represent transcriptional units. Two-dimensional hierarchical clustering classifies 72
differential expression profiles into two expression cluster groups according to the similarity of their expression profiles. Their identities and expression patterns are listed in Tables S1
and S2.
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property is mainly due to an increase in glycolytic flux which is caused
by up-regulated expression and, in parts, by biochemical activation of
membrane-based transporters for glucose and monocarboxylates and
of glycolytic enzymes as a consequence ofmetabolic and oncogenic reg-
ulation (Koukourakis et al., 2006). Hypoxia can shift the balance of en-
ergy production towards anaerobic glycolysis with production of
lactate, but many tumours exhibit a strong generation of lactate even
in the presence of oxygen. This phenomenonwhich is known as ‘aerobic
glycolysis’ or the ‘Warburg effect’ is generally considered to be the re-
sult of oncogenic alteration in glucose metabolism following malignant
transformation (Kroemer & Pouyssegur, 2008). The concomitant induc-
tion of angiogenesis and glycolysis with cell proliferation is mediatedFig. 5. Histogram presentation of Gene Ontology (GO) classification. The results are
summarized in three main categories: biological process, molecular function and cellular
component. The y-axis indicates the number of genes in a category. In three main
categories of GO classification, there are 27, 10 and 12 functional groups in ISL
treatment and 27, 10, and 11 functional groups in RA treatment, respectively. Among
these groups, the GO terms binding (GO: 0005488) in the molecular function categories
and response to stimulus in the biological process categories (GO: 0050896) were both
dominant in the treatment both of ISL and RA.partly by activating hypoxia-inducible transcriptional factor (HIF-1).
Hypoxia increases HIF-1 levels in most cell types and HIF-1 mediates
adaptative responses to changes in tissue oxygenation. Thus, HIF-1
can directly up-regulate expression of a set of genes involved in both
local and global reaction to hypoxia, including angiogenesis, erythropoi-
esis, breathing andmost of the glycolytic enzymes: HK1, HK2, AMF/GPI,
ENO1, GLUT1, GADPH, LDHA, PFKBF3, PFKL, PGK1, PKM, TPI (Semenza,
1998). These data support a functional link between enhanced glycoly-
sis and cellular oxidative stress adaptation during tumor formation and
expansion. ROS (reactive oxygen species) is the main source of oxida-
tive stress. Normal levels of cellular ROS canwork as secondmessengers
involved in several signal transduction pathways (such as the Ras-Raf-
MEK cascade) (Dang, 2007). But abnormal ROS accumulation and its
side-effects over intracellular macromolecules (oxidation of lipid, pro-
tein and DNA) provokes cumulative damage at cell, tissue, and organ-
ism level, and even cause tumor differentiation (Chen et al., 2012).
Our previous result revealed that the ROS level increased during mela-
noma differentiation induced by ISL. Increased ROS accumulation may
disturb the hypoxia environment for melanoma including causing
ROS-mediated fixation of DNA damage and induction of radio resis-
tance. In our RNA-seq data, glutathione metabolism-related genes
were up-regulated and glycolysis-related genes were down-regulated.
This finding may be connected with the key molecular HIF-1. HIF-1
transcriptionally regulatesmost of glycolytic geneswith the only excep-
tion of PGM (Niizeki et al., 2002). It suggested that ISL-induced ROS in-
crease may decrease the expression of HIF-1 while resulting in a
reduction of HK 2 expression to adapt high ROS state. Meanwhile, Glu-
tathione (GSH: reduced glutathione; GSSG: oxidised glutathione)
which is quantitatively the most important cellular redox system was
also increased by ISL to induce a reducedmilieu formelanoma. The pen-
tose phosphate pathway (PPP), i.e., the activity of glucose-6-phosphate
dehydrogenase, plays a prominent role to continuously yield NADPH+
H+ to keep glutathione in the reduced state. The three vital metabolism
pathways which DGEs significantly enrich may probably provide in-
sights into the molecular mechanisms of the melanoma differentiation
induced by ISL.
Our data set also allow us to identify pathway in RA-induced mela-
noma differentiation. The KEGG analysis indicated that the most of
Fig. 6. Scatter plot of KEGG pathway enrichment statistics and the most enrichment pathway during the treatment of ISL or RA. (A) Top 20 statistics of pathway enrichment after ISL
treatment. (B) Top 20 statistics of pathway enrichment after RA treatment. (C) Glutathione metabolism signaling pathway (D) MAPK signaling pathway. Red and green frames
indicate genes and enriched functions that were up- and down-regulated in drug treatment.
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activated protein kinases (MAPKs) are serine-threonine kinases that
mediate intracellular signaling associated with a variety of cellular ac-
tivities including cell proliferation, differentiation, survival, death, and
transformation (McCubrey et al., 2007; Dhillon et al., 2007). Interesting-
ly, previous work had found many different MAPKs cascades can be ac-
tivated following ROS accumulation. These include the ROS-responsive
MAPKKK MEKK1, MPK4 and MPK6 (Jammes et al., 2009). MAPK path-
ways are also implicated in the induction of nitric oxide (NO) and ROS
bursts and signaling, which synergistically function in defense re-
sponses (Asai et al., 2008). Both NO and ROS were reported to be pro-
duced simultaneously through the MAPK cascade MEK2-SIPK (salicylic
acid-induced protein kinase) (Demidchik et al., 2009). Except for the
findings as previously reported, we also predicted several potential
genes inMAPK signaling pathway. This finding provides a good founda-
tion for further research on the discovery of new genes and facilitates
the understanding of RA induced melanoma differentiation.
There have been a number of earlier reports of differentiation related
gene. Here, we apply ISL or RA inducedmelanomadifferentiation to pre-
dict melanoma related differentiation gene. In the analysis of hierarchi-
cal clustering of DEGs, we discover 72 DEGs. In 72 DEGs, there were 32
DEGs up-regulated, and 30 DEGs down-regulated in both ISL and RA
treatment. Among these genes, we found Cited1, Tgm2, Xaf1, Cd59a,
Fbxo2, Adh7 were highly expressed in both ISL and RA treatment. Wesuggested an important role on melanoma differentiation of these
genes. Xaf1 was expressed in top 10 within ISL treatment and top 30
after treated by RA. Cited1 is a non-DNA binding transcriptional co-
regulator whose expression can distinguish the ‘proliferative’ from ‘in-
vasive’ signature in the phenotype-switching model of melanoma. It is
reported Cited1 positively correlates with Mitf expression and can dis-
criminate the MITF-high/pigmentation tumor molecular subtype in a
large cohort (120) of melanoma cell lines (Howlin et al., 2015). Besides,
Mitf functioned in a range compatible with tumourigenesis. So, we
could speculate B16F0 melanoma showed a high pigmentation ability
and a loss malignant characterization after both ISL and RA. Furthermore,
Yang D et al. found Cited1 modulates parathyroid hormone regulation of
osteoblastic differentiation (Yang et al., 2008). Plisov S et al. thought
Cited1 may coordinate cellular differentiation and survival signals that
regulate nephronic patterning in the metanephros (Plisov et al., 2005).
These reports indicated Cited1 may contribute to the differentiation
of melanoma. Previously, there were studies had reported TGM2
and ADH7 are involved in retinoic acid-induced transdifferentiation
(Obinata et al., 2011). Previous study also suggests that TGM2 is useful
as a predictivemarker for patient prognosis andmay be a novel therapeu-
tic target for colorectal cancer and breast cancer (Miyoshi et al., 2010; Ai
et al., 2008). This is the first report to show TGM2 and ADH7 highly
expressed in ISL induced melanoma differentiation. We suggested these
genes may have important functions in melanoma differentiation.
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event is that we only usemelanoma cell lines and differentiation induc-
er treated melanoma cell lines. For limited experimental condition, our
group of experiment lack of homologous melanocyte melan-a cell line
as normal control. For sequencing method, we applied the single-end
sequencing. Although this approach could be highly sensitive, it also re-
sults in high false positive rate. Further work using longer sequencing
reads or using paired-end sequencingwill help to alleviate the problem.
In conclusion, this study for the first time utilized next generation
sequencing platform to comprehensively characterize the process of
melanoma differentiation. The full characterize of the landscapes of
melanoma transcriptome provides the basis for an understanding of
themolecularmechanism of compound inducedmelanoma differentia-
tion. Future researchworks based on our findingsmay speed up the dis-
covery of novel biomarkers and drug targets for improving diagnosis
and therapy of melanoma.
5. Conclusion
Melanoma represents a significant and growing public health bur-
den worldwide. Our previous evidence clearly demonstrates that ISL
could induce melanoma cell line B16F0 differentiation which provide
a new way to cue melanoma. Then, we deeply dig the mechanisms of
ISL-induced B16F0 differentiation by next generation sequencing
(NGS). Interesting findings showed in our research: anti-oxidative de-
fense and glycometabolism are critical process in the ISL-inducedmela-
noma differentiation. These findings provide a molecular basis for ISL-
induced melanoma differentiation process. This investigation has also
provided insight into the mechanism of melanoma differentiation in
RA treatment. After the interference of RA, DEGs reveals inMAPK signal-
ing pathway. It seems that the pattern of ISL and RA inducedmelanoma
differentiation is quite different. We also detects 72 DEGs which proba-
bly related to melanoma differentiation. Our future research based on
these findings may speed up the discovery of novel biomarkers of mel-
anoma differentiation and drug targets for improving diagnosis and
therapy of melanoma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2016.07.052.
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